Stomec

Stomec may be available in the countries listed below.

Ingredient matches for Stomec

Omeprazole

Omeprazole is reported as an ingredient of Stomec in the following countries:

• Thailand

International Drug Name Search

Hydrocortison Galepharm

Hydrocortison Galepharm may be available in the countries listed below.

Ingredient matches for Hydrocortison Galepharm

Hydrocortisone

Hydrocortisone is reported as an ingredient of Hydrocortison Galepharm in the following countries:

• Switzerland

International Drug Name Search

diphtheria, tetanus, and pertussis (DTaP) vaccines

Generic Name: diphtheria, tetanus, and pertussis (DTaP) vaccines (DIF thee ree ah, TET ah nus, per TUH sis)

Brand names: Acel-Imune, Certiva, Daptacel, Infanrix, Tripedia, ...show all 11 brand names.Acel-Immune, Tripedia (obsolete), Infanrix (obsolete), Daptacel (obsolete), Boostrix (obsolete), Adacel (obsolete)

What are diphtheria, tetanus, and pertussis vaccines?

Diphtheria, tetanus, and pertussis are serious diseases caused by bacteria.

Diphtheria causes a thick coating in the nose, throat, and airway. It can lead to breathing problems, paralysis, heart failure, and even death.

Tetanus (lockjaw) causes painful tightening of the muscles, usually all over the body. It can lead to "locking" of the jaw so the victim cannot open his mouth or swallow. Tetanus leads to death in about 1 out of 10 cases.

Pertussis (whooping cough) causes coughing so severe that it is hard for infants to eat, drink, or breathe. These spells can last for weeks. It can lead to pneumonia, seizures (convulsions), brain damage, and death.

Diphtheria and pertussis are spread from person to person. Tetanus enters the body through cuts or wounds. Vaccines for these diseases expose the individual to a small amount of the bacteria, helping the body develop immunity to the disease.

Diphtheria, tetanus, and pertussis vaccine (DTaP) can help prevent these diseases. Most children who are vaccinated with DTaP will be protected throughout childhood.

What is the most important information I should know about diphtheria, tetanus, and pertussis vaccines?

Children should get 5 doses of DTaP vaccine, one dose at each of the following ages: 2 months, 4 months, 6 months, 15 to 18 months, and 4 to 6 years. The series should be completed before the child's seventh birthday.

Keep track of any and all side effects your child has after receiving this vaccine. When the child receives the next booster dose, you will need to tell the doctor if the first shot caused any side effects. Getting diphtheria, tetanus, or pertussis disease is much riskier than getting DTaP vaccine. However, like any medicine, this vaccine can cause side effects. The risk of DTaP vaccine causing a serious side effect is extremely small.

Any child who had a life-threatening allergic reaction after a dose of DTaP should not receive another dose. Any child who has had encephalitis (brain swelling) or a brain or nervous system disease within 7 days after a dose of DTaP should not receive another dose.

Children with a cold or fever can still be vaccinated. Children who are moderately or severely ill should usually wait until they recover before getting DTaP vaccine.

What should I discuss with my healthcare provider before receiving diphtheria, tetanus, and pertussis vaccines?

Any child who had a life-threatening allergic reaction after a dose of DTaP should not receive another dose. Any child who has had encephalitis (brain swelling) or a brain or nervous system disease within 7 days after a dose of DTaP should not receive another dose.

Before receiving DTaP vaccine, talk to your doctor if your child:

• 
  

  had a seizure or collapsed after a dose of DTaP;

  
  


• 
  

  cried non-stop for 3 hours or more after a dose of DTaP;

  
  


• 
  

  had a fever over 105 degrees after a dose of DTaP;

  
  


• 
  

  developed Guillian-Barre syndrome within 6 weeks after a prior tetanus shot;

  
  


• 
  

  has HIV or AIDS or another disease that affects the immune system;

  
  


• 
  

  is taking a medication that affects the immune system (steroids, anti-rejection medications after a transplant);

  
  


• 
  

  has a bleeding disorder or takes blood thinners (such as warfarin or Coumadin);

  
  


• 
  

  has cancer; or

  
  


• 
  

  is receiving cancer treatment with x-rays, radiation, or medication.

  
  

If the child has any of these conditions, he or she may not be able to receive DTaP.

Children with a cold or fever can still be vaccinated. Children who are moderately or severely ill should usually wait until they recover before getting DTaP vaccine.

FDA pregnancy category C: This medication may be harmful to an unborn baby and should not be given to a woman who is pregnant.

How are diphtheria, tetanus, and pertussis vaccines administered?

This vaccine is given as an injection into a muscle. A doctor, nurse, or other healthcare provider will give this injection.

Children should get 5 doses of DTaP vaccine, one dose at each of the following ages: 2 months, 4 months, 6 months, 15 to 18 months, and 4 to 6 years. The series should be completed before the child's seventh birthday.

Your doctor may recommend reducing fever and pain by giving the child an aspirin-free pain reliever such as acetaminophen (Tylenol, Tempra, others) or ibuprofen (Motrin, Advil, others) when the shot is given and for the next 24 hours. Your healthcare provider can tell you the appropriate dosages of these medications. Controlling fever is especially important for children who have had seizures for any reason, or if a family member has had seizures.

What happens if I miss a dose?

Contact your doctor if a dose of DTaP vaccine is missed.

What happens if I overdose?

An overdose of DTaP vaccine is unlikely to occur.

What should I avoid before or after getting diphtheria, tetanus, and pertussis vaccines?

There are no restrictions on food, beverages, or activity before or after receiving DTaP vaccine unless your doctor has told you otherwise.

Diphtheria, tetanus, and pertussis vaccines side effects

Keep track of any and all side effects your child has after receiving this vaccine. When the child receives the next booster dose, you will need to tell the doctor if the first shot caused any side effects. Getting diphtheria, tetanus, or pertussis disease is much riskier than getting DTaP vaccine. However, like any medicine, this vaccine, can cause side effects. The risk of DTaP vaccine causing a serious side effect is extremely small.

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.

Call your doctor at once if the child has any of the following serious side effects:

• 
  

  loss of consciousness;

  
  


• 
  

  seizure (black-out or convulsions);

  
  


• 
  

  high fever, over 105 degrees; or

  
  


• 
  

  non-stop crying for 3 hours or more.

  
  

Other less serious side effects may be more likely to occur. Talk to your doctor if your child has:

• 
  

  mild fever;

  
  


• 
  

  redness, pain, tenderness, or swelling where the shot was given;

  
  


• 
  

  fussiness for 1-3 days after the shot;

  
  


• 
  

  tiredness or poor appetite for 1-3 days after the shot; or

  
  


• 
  

  vomiting for 1-3 days after the shot.

  
  

Side effects other than those listed here may also occur. Talk to your doctor about any side effect that seems unusual or that is especially bothersome.

To help reduce fever and pain, your doctor may recommend giving the child an aspirin-free pain reliever such as acetaminophen (Tylenol, Tempra, others) or ibuprofen (Motrin, Advil). This may be given at the time of the shot and over the next 24 hours. Your doctor will tell you the correct dose to use. Controlling fever is especially important if the child has a history of seizures.

Diphtheria, tetanus, and pertussis (DTaP) vaccines Dosing Information

Usual Adult Dose for Diphtheria Prophylaxis:

Booster Immunization:
ADACEL (R):
18 to 64 years: 0.5 mL IM once. Individuals who have completed a primary series against tetanus and who sustain wounds which are minor and uncomplicated, should receive a booster dose of a tetanus toxoid containing vaccine only if they have not received a tetanus toxoid within the preceding 10 years. For tetanus prone wounds, a booster is appropriate if the patient has not received a tetanus toxoid containing preparation within the preceding 5 years.

Usual Adult Dose for Pertussis Prophylaxis:

Booster Immunization:
ADACEL (R):
18 to 64 years: 0.5 mL IM once. Individuals who have completed a primary series against tetanus and who sustain wounds which are minor and uncomplicated, should receive a booster dose of a tetanus toxoid containing vaccine only if they have not received a tetanus toxoid within the preceding 10 years. For tetanus prone wounds, a booster is appropriate if the patient has not received a tetanus toxoid containing preparation within the preceding 5 years.

Usual Adult Dose for Tetanus Prophylaxis:

Booster Immunization:
ADACEL (R):
18 to 64 years: 0.5 mL IM once. Individuals who have completed a primary series against tetanus and who sustain wounds which are minor and uncomplicated, should receive a booster dose of a tetanus toxoid containing vaccine only if they have not received a tetanus toxoid within the preceding 10 years. For tetanus prone wounds, a booster is appropriate if the patient has not received a tetanus toxoid containing preparation within the preceding 5 years.

Usual Pediatric Dose for Diphtheria Prophylaxis:

Primary Immunization Series:

DAPTACEL (R):
6 weeks to 6 years (prior to seventh birthday): 0.5 mL IM given as a 4 dose series at 2,4, and 6 months of age, at intervals of 6 to 8 weeks and at 17 to 20 months of age. The interval between the 3rd and 4th dose should be at least 6 months.

INFANRIX (R):
6 weeks to 7 years (prior to seventh birthday): 0.5 mL IM given as a 5 dose series. The series consists of a primary immunization course of 3 doses administered at 2,4, and 6 months of age, followed by 2 booster doses, administered at 15 to 20 months of age and at 4 to 6 years of age. The recommended interval between the first three doses is 8 weeks, with a minimum interval of 4 weeks. The recommended interval between the 3rd and 4th dose is 6 to 12 months. The fifth dose is recommended before entry into kindergarten or elementary school, and is not needed if the fourth dose was given after the fourth birthday.

Tripedia (R):
6 weeks to 7 years (prior to seventh birthday): 0.5 mL IM given as a 5 dose series. The series consists of a primary immunization course of 3 doses administered at 2,4, and 6 months of age, followed by 2 booster doses, administered at 15 to 18 months of age and at 4 to 6 years of age. The recommended interval between the first three doses is 8 weeks, with a minimum interval of 4 weeks. The recommended interval between the 3rd and 4th dose is 6 to 12 months. The fifth dose is recommended before entry into kindergarten or elementary school, and is not needed if the fourth dose was given after the fourth birthday.

Booster Immunization:

BOOSTRIX (R):
10 to 18 years: 0.5 mL IM once. Five years should have elapsed between the administration of BOOSTRIX and the last dose of the recommended series of childhood DTwP and/or DTaP vaccine. Adolescents 10 to 18 years of age who have completed a primary series against tetanus and who sustain wounds which are minor and uncomplicated, should receive a booster dose of a tetanus toxoid containing vaccine only if they have not received a tetanus toxoid within the preceding 10 years.

ADACEL (R):
11 to 18 years: 0.5 mL IM once. Individuals who have completed a primary series against tetanus and who sustain wounds which are minor and uncomplicated, should receive a booster dose of a tetanus toxoid containing vaccine only if they have not received a tetanus toxoid within the preceding 10 years. For tetanus prone wounds, a booster is appropriate if the patient has not received a tetanus toxoid containing preparation within the preceding 5 years.

Usual Pediatric Dose for Pertussis Prophylaxis:

Primary Immunization Series:

DAPTACEL (R):
6 weeks to 6 years (prior to seventh birthday): 0.5 mL IM given as a 4 dose series at 2,4, and 6 months of age, at intervals of 6 to 8 weeks and at 17 to 20 months of age. The interval between the 3rd and 4th dose should be at least 6 months.

INFANRIX (R):
6 weeks to 7 years (prior to seventh birthday): 0.5 mL IM given as a 5 dose series. The series consists of a primary immunization course of 3 doses administered at 2,4, and 6 months of age, followed by 2 booster doses, administered at 15 to 20 months of age and at 4 to 6 years of age. The recommended interval between the first three doses is 8 weeks, with a minimum interval of 4 weeks. The recommended interval between the 3rd and 4th dose is 6 to 12 months. The fifth dose is recommended before entry into kindergarten or elementary school, and is not needed if the fourth dose was given after the fourth birthday.

Tripedia (R):
6 weeks to 7 years (prior to seventh birthday): 0.5 mL IM given as a 5 dose series. The series consists of a primary immunization course of 3 doses administered at 2,4, and 6 months of age, followed by 2 booster doses, administered at 15 to 18 months of age and at 4 to 6 years of age. The recommended interval between the first three doses is 8 weeks, with a minimum interval of 4 weeks. The recommended interval between the 3rd and 4th dose is 6 to 12 months. The fifth dose is recommended before entry into kindergarten or elementary school, and is not needed if the fourth dose was given after the fourth birthday.

Booster Immunization:

BOOSTRIX (R):
10 to 18 years: 0.5 mL IM once. Five years should have elapsed between the administration of BOOSTRIX and the last dose of the recommended series of childhood DTwP and/or DTaP vaccine. Adolescents 10 to 18 years of age who have completed a primary series against tetanus and who sustain wounds which are minor and uncomplicated, should receive a booster dose of a tetanus toxoid containing vaccine only if they have not received a tetanus toxoid within the preceding 10 years.

ADACEL (R):
11 to 18 years: 0.5 mL IM once. Individuals who have completed a primary series against tetanus and who sustain wounds which are minor and uncomplicated, should receive a booster dose of a tetanus toxoid containing vaccine only if they have not received a tetanus toxoid within the preceding 10 years. For tetanus prone wounds, a booster is appropriate if the patient has not received a tetanus toxoid containing preparation within the preceding 5 years.

Usual Pediatric Dose for Tetanus Prophylaxis:

Primary Immunization Series:

DAPTACEL (R):
6 weeks to 6 years (prior to seventh birthday): 0.5 mL IM given as a 4 dose series at 2,4, and 6 months of age, at intervals of 6 to 8 weeks and at 17 to 20 months of age. The interval between the 3rd and 4th dose should be at least 6 months.

INFANRIX (R):
6 weeks to 7 years (prior to seventh birthday): 0.5 mL IM given as a 5 dose series. The series consists of a primary immunization course of 3 doses administered at 2,4, and 6 months of age, followed by 2 booster doses, administered at 15 to 20 months of age and at 4 to 6 years of age. The recommended interval between the first three doses is 8 weeks, with a minimum interval of 4 weeks. The recommended interval between the 3rd and 4th dose is 6 to 12 months. The fifth dose is recommended before entry into kindergarten or elementary school, and is not needed if the fourth dose was given after the fourth birthday.

Tripedia (R):
6 weeks to 7 years (prior to seventh birthday): 0.5 mL IM given as a 5 dose series. The series consists of a primary immunization course of 3 doses administered at 2,4, and 6 months of age, followed by 2 booster doses, administered at 15 to 18 months of age and at 4 to 6 years of age. The recommended interval between the first three doses is 8 weeks, with a minimum interval of 4 weeks. The recommended interval between the 3rd and 4th dose is 6 to 12 months. The fifth dose is recommended before entry into kindergarten or elementary school, and is not needed if the fourth dose was given after the fourth birthday.

Booster Immunization:

BOOSTRIX (R):
10 to 18 years: 0.5 mL IM once. Five years should have elapsed between the administration of BOOSTRIX and the last dose of the recommended series of childhood DTwP and/or DTaP vaccine. Adolescents 10 to 18 years of age who have completed a primary series against tetanus and who sustain wounds which are minor and uncomplicated, should receive a booster dose of a tetanus toxoid containing vaccine only if they have not received a tetanus toxoid within the preceding 10 years.

ADACEL (R):
11 to 18 years: 0.5 mL IM once. Individuals who have completed a primary series against tetanus and who sustain wounds which are minor and uncomplicated, should receive a booster dose of a tetanus toxoid containing vaccine only if they have not received a tetanus toxoid within the preceding 10 years. For tetanus prone wounds, a booster is appropriate if the patient has not received a tetanus toxoid containing preparation within the preceding 5 years.

What other drugs will affect diphtheria, tetanus, and pertussis vaccines?

Before receiving the DTaP vaccine, tell the doctor if the child is using any of the following medications:

• 
  

  an oral, nasal, inhaled, or injectable steroid medicine;

  
  


• 
  

  cancer chemotherapy or radiation;

  
  


• 
  

  azathioprine (Imuran);

  
  


• 
  

  basiliximab (Simulect);

  
  


• 
  

  cyclosporine (Sandimmune, Neoral, Gengraf);

  
  


• 
  

  etanercept (Enbrel);

  
  


• 
  

  leflunomide (Arava);

  
  


• 
  

  muromonab-CD3 (Orthoclone);

  
  


• 
  

  mycophenolate mofetil (CellCept);

  
  


• 
  

  sirolimus (Rapamune); or

  
  


• 
  

  tacrolimus (Prograf).

  
  

There may be other drugs not listed that can affect the DTaP vaccine. Tell your doctor about all the prescription and over-the-counter medications the child uses. This includes vitamins, minerals, herbal products, and drugs prescribed by other doctors.

Where can I get more information?

• Your doctor or pharmacist may have additional information or suggest additional resources regarding DTaP vaccine.

Dotarem

Dotarem may be available in the countries listed below.

Ingredient matches for Dotarem

Gadoteric Acid

Gadoteric Acid is reported as an ingredient of Dotarem in the following countries:

• Finland


• Italy


• Spain


• Sweden

Gadoteric Acid meglumine (a derivative of Gadoteric Acid) is reported as an ingredient of Dotarem in the following countries:

• Argentina


• Australia


• Austria


• Belgium


• Bosnia & Herzegowina


• Chile


• Croatia (Hrvatska)


• Czech Republic


• Denmark


• France


• Germany


• Greece


• Hungary


• Israel


• Luxembourg


• Norway


• Portugal


• Serbia


• Switzerland


• Tunisia


• Turkey


• Venezuela

International Drug Name Search

Curadon

Curadon may be available in the countries listed below.

Ingredient matches for Curadon

Paracetamol

Paracetamol is reported as an ingredient of Curadon in the following countries:

• Sweden

International Drug Name Search

Efevelone

Efevelone may be available in the countries listed below.

Ingredient matches for Efevelone

Venlafaxine

Venlafaxine is reported as an ingredient of Efevelone in the following countries:

• Russian Federation

International Drug Name Search

Kanamycin Ogris

Kanamycin Ogris may be available in the countries listed below.

In some countries, this medicine may only be approved for veterinary use.

Ingredient matches for Kanamycin Ogris

Kanamycin

Kanamycin sulfate (a derivative of Kanamycin) is reported as an ingredient of Kanamycin Ogris in the following countries:

• Austria

International Drug Name Search

Magicul

Magicul may be available in the countries listed below.

Ingredient matches for Magicul

Cimetidine

Cimetidine is reported as an ingredient of Magicul in the following countries:

• Australia

International Drug Name Search

Ammonio cloruro Galenica

Ammonio cloruro Galenica may be available in the countries listed below.

Ingredient matches for Ammonio cloruro Galenica

Ammonium Chloride

Ammonium Chloride is reported as an ingredient of Ammonio cloruro Galenica in the following countries:

• Italy

International Drug Name Search